Trial Search Results

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

In this study the investigators are trying to identify immune signatures that are associated with effective or poor vaccine responses to naturally-acquired herpes zoster virus and the zoster (shingles) vaccine, Zostavax.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)

Stanford Investigator(s):


  • Biological: Zostavax™


Phase 4


Inclusion Criteria:

   - Otherwise healthy adult non-twins and twin pairs, 40-49 years of age (Cross-Sectional
   study) or 50 years of age and older (Vaccination study). If a volunteer cannot
   participate in the Vaccination study after screening, may be considered for
   Cross-Sectional study.

   - History of prior chicken pox infection or living within the continental U.S. for past
   30 years

   - Willing to complete the informed consent process

   - Availability for follow-up for the planned duration of the study (Cross-Sectional
   study: 1 visit; Vaccination study: 5 visits within 4-5 weeks)

   - Acceptable medical history and vital signs

Exclusion Criteria:

   - History of shingles within 5 years of enrollment

   - Prior vaccination with Zostavax vaccine for prevention of shingles

   - Vaccination Study only: History of severe allergic reactions to vaccine components,
   including gelatin and neomycin.

   - Vaccination Study only: Life-threatening reactions to previous vaccinations.

   - Vaccination Study only: Adults weighing less than 110 pounds.

   - Active systemic or serious concurrent illness, including febrile illness on the day of

   - History of immunodeficiency disorder

   - Chronic HIV, Hepatitis B or Hepatitis C infection

   - Known or suspected impairment of immunologic function, including, but not limited to
   clinically significant liver disease, diabetes mellitus treated with insulin, moderate
   to severe renal disease or any other chronic disorder which, in the opinion of the
   investigator, might jeopardize volunteer safety or compliance with the protocol.

   - Recent or current use of immunosuppressive medication, or anticipated use during study
   period, including systemic corticosteroids (corticosteroid nasal sprays, inhaled
   steroids and topical steroids are permissible).

   - Blood pressure >150 systolic or > 95 diastolic at Visit 1

   - History of chemotherapy treatment for cancer.

   - Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors
   such as breast cancer with recurrence in the past year and any hematologic cancer such
   as leukemia or lymphoma) which, in the opinion of the investigator, might jeopardize
   volunteer safety or compliance with the protocol. Prostate cancer may be acceptable if
   no metastases and not undergoing treatment with immunosuppressive medications.

   - Autoimmune disease, including rheumatoid arthritis, treated with immunosuppressive
   medication such as Plaquenil, methotrexate, prednisone, Enbrel, which in the opinion
   of the investigator, might jeopardize volunteer safety or compliance with the protocol
   (thyroid disease may be acceptable).

   - History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
   medical follow up or hospitalization during the preceding year

   - Use of anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet
   agents such as aspirin (except aspirin up to 325 mg. daily), Plavix or Aggrenox which
   may, in the opinion of the investigator, jeopardize volunteer safety or compliance
   with the protocol.

   - Receipt of blood or blood products within 6 months prior to enrollment and during the
   study period

   - Use of antiviral medications within 24 hrs. prior to enrollment, and for the
   Vaccination study, for the 14 days following study vaccination.

   - Inactivated vaccine within 14 days prior to enrollment and during study period(avoid
   non-study related immunization during the study period)

   - Live, attenuated vaccine within 60 days prior to enrollment and during study period
   (avoid non-study related immunization during the study period)

   - Pregnant or lactating woman, planning to become pregnant (pregnancy should be avoided
   for 3 months following administration of Zostavax vaccine).

   - Use of investigational agents within 30 days prior to enrollment and during study

   - Donation of a unit of blood within 6 weeks prior to enrollment and during study period

   - Medical or psychiatric condition or occupational responsibilities that preclude
   subject compliance with the protocol

   - Any condition which, in the opinion of the investigator, might interfere with
   volunteer safety, study objectives or the ability of the participant to understand or
   comply with the study protocol.

Ages Eligible for Study

40 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305